Compare EPM & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPM | ARMP |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 158.2M | 383.7M |
| IPO Year | 1996 | 1996 |
| Metric | EPM | ARMP |
|---|---|---|
| Price | $4.49 | $9.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $4.93 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 412.9K | 40.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 10.46% | N/A |
| EPS Growth | N/A | ★ 53.40 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $43,229,621.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $92.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.19 | $0.90 |
| 52 Week High | $5.70 | $13.75 |
| Indicator | EPM | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 53.70 | 50.10 |
| Support Level | $4.38 | $5.14 |
| Resistance Level | $4.63 | $12.11 |
| Average True Range (ATR) | 0.16 | 0.96 |
| MACD | -0.02 | -0.27 |
| Stochastic Oscillator | 37.17 | 17.65 |
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.